A Cautious Outlook for Viking Therapeutics Amid Critical Clinical Trials

Analyst downgrades Viking stock to Hold, citing Phase 3 risks and competition. Key oral drug data and commercial plans are set for 2026 updates.

Viking Therapeutics is entering a pivotal period in its quest to capture a share of the multi-billion dollar weight-loss drug market. As the biotech firm aggressively expands clinical testing for its candidate, VK2735, a note of caution is emerging from analysts, tempering the recent investor enthusiasm with a focus on the risks inherent in the final stages of drug development.

Analyst Downgrade Highlights Competitive and Clinical Risks

A shift in sentiment occurred on March 19, 2026, when an analyst from Seeking Alpha revised their rating on Viking Therapeutics shares from "Buy" to "Hold." The analyst cited intensifying competition within the GLP-1 drug sector and the significant binary risks associated with upcoming Phase 3 trials as primary concerns. This downgrade has applied pressure to the stock's recent recovery; just in February, shares had rallied approximately 16.5% following a quarterly earnings report. The current advice to investors is to await data from a maintenance dose study expected in the third quarter before considering new positions.

Ambitious Trial Schedule and Tolerability Questions

The company's clinical calendar is exceptionally full, with the potential to run four concurrent Phase 3 studies by year-end. In addition to the ongoing VANQUISH trials for the subcutaneous formulation of VK2735, an oral version of the drug is slated to enter its crucial testing phase in Q3 2026. This oral formulation is under particular scrutiny.

While Phase 2 data released in August 2025 demonstrated impressive efficacy—showing an average weight reduction of 12.2% over 13 weeks—it also revealed tolerability issues. Notably, 20% of trial participants discontinued treatment due to gastrointestinal side effects. To address this, a bridging study is currently underway where participants begin with an injectable dose before switching to an oral maintenance regimen. This fully enrolled study's results are also anticipated in the third quarter.

Commercial Foundations Are Being Laid

Despite the clinical hurdles, Viking's management is not waiting to build commercial infrastructure. A comprehensive agreement with contract manufacturer CordenPharma secures production capacity for up to 100 million auto-injectors and one billion tablets annually. To lock in this capacity, Viking is committed to upfront payments totaling $150 million through 2028. The firm is targeting a global market share between 5% and 10%. Competition remains fierce, however, as industry leader Eli Lilly continues to extend its lead in the obesity treatment market.

Investors can expect the next significant update on April 21, 2026. On this date, Viking Therapeutics is scheduled to report financial results for the latest quarter and provide a detailed operational update, including its current cash burn rate and pipeline progress.